
When a Co-Pay Gets in the Way of Health
Economists specialize in pointing out unpleasant trade-offs - a skill that is on full display in the health care debate.
Economists specialize in pointing out unpleasant trade-offs — a skill that is on full display in the health care debate.
We want patients to receive the best care available. We also want consumers to pay less. And we don’t want to bankrupt the government or private insurers. Something must give.
The debate centers on how to make these trade-offs, and who gets to make them. The stakes are high, and the choices are at times unseemly. No matter how necessary, putting human suffering into dollars and cents is not attractive work. It’s no surprise, then, that the conversation is so heated.
	What is a surprise is that amid these complex issues, one policy sidesteps these trade-offs. A few drugs — such as beta-blockers, statins and glycogen control medications — have proved very effective at managing 
	Read the full story here: 
Source: NY Times
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.















































